File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)

Article: Next-generation sequencing with a 54-gene panel identified unique mutational profile and prognostic markers in Chinese patients with myelofibrosis

TitleNext-generation sequencing with a 54-gene panel identified unique mutational profile and prognostic markers in Chinese patients with myelofibrosis
Authors
KeywordsMyelofibrosis
Primary
Secondary
Next-generation sequencing
Prognosis
Issue Date2018
PublisherSpringer Verlag. The Journal's web site is located at http://link.springer.de/link/service/journals/00277/index.htm
Citation
Annals of Hematology, 2018 How to Cite?
AbstractCurrent prognostication in myelofibrosis (MF) is based on clinicopathological features and mutations in a limited number of driver genes. The impact of other genetic mutations remains unclear. We evaluated for mutations in a myeloid panel of 54 genes using next-generation sequencing. Multivariate Cox regression analysis was used to determine prognostic factors for overall survival (OS) and leukaemia-free survival (LFS), based on mutations of these genes and relevant clinical and haematological features. One hundred and one patients (primary MF, N = 70; secondary MF, N = 31) with a median follow-up of 49 (1–256) months were studied. For the entire cohort, inferior OS was associated with male gender (P = 0.04), age > 65 years (P = 0.04), haemoglobin < 10 g/dL (P = 0.001), CUX1 mutation (P = 0.003) and TP53 mutation (P = 0.049); and inferior LFS was associated with male gender (P = 0.03), haemoglobin < 10 g/dL (P = 0.04) and SRSF2 mutations (P = 0.008). In primary MF, inferior OS was associated with male gender (P = 0.03), haemoglobin < 10 g/dL (P = 0.002), platelet count < 100 × 109/L (P = 0.02), TET2 mutation (P = 0.01) and CUX1 mutation (P = 0.01); and inferior LFS was associated with haemoglobin < 10 g/dL (P = 0.02), platelet count < 100 × 109/L (P = 0.02), TET2 mutations (P = 0.01) and CUX1 mutations (P = 0.04). These results showed that clinical and haematological features and genetic mutations should be considered in MF prognostication.
Persistent Identifierhttp://hdl.handle.net/10722/265965
ISSN
2017 Impact Factor: 2.845
2015 SCImago Journal Rankings: 1.117

 

DC FieldValueLanguage
dc.contributor.authorSingh, GHH-
dc.contributor.authorIp, HW-
dc.contributor.authorYim, RLH-
dc.contributor.authorTang, WF-
dc.contributor.authorPang, HMH-
dc.contributor.authorLee, P-
dc.contributor.authorLeung, GMK-
dc.contributor.authorLi, JWY-
dc.contributor.authorTang, K-
dc.contributor.authorSo, JCC-
dc.contributor.authorLeung, RYY-
dc.contributor.authorLi, J-
dc.contributor.authorPanagiotou, I-
dc.contributor.authorLam, CCK-
dc.contributor.authorKwong, YL-
dc.date.accessioned2018-12-17T02:16:23Z-
dc.date.available2018-12-17T02:16:23Z-
dc.date.issued2018-
dc.identifier.citationAnnals of Hematology, 2018-
dc.identifier.issn0939-5555-
dc.identifier.urihttp://hdl.handle.net/10722/265965-
dc.description.abstractCurrent prognostication in myelofibrosis (MF) is based on clinicopathological features and mutations in a limited number of driver genes. The impact of other genetic mutations remains unclear. We evaluated for mutations in a myeloid panel of 54 genes using next-generation sequencing. Multivariate Cox regression analysis was used to determine prognostic factors for overall survival (OS) and leukaemia-free survival (LFS), based on mutations of these genes and relevant clinical and haematological features. One hundred and one patients (primary MF, N = 70; secondary MF, N = 31) with a median follow-up of 49 (1–256) months were studied. For the entire cohort, inferior OS was associated with male gender (P = 0.04), age > 65 years (P = 0.04), haemoglobin < 10 g/dL (P = 0.001), CUX1 mutation (P = 0.003) and TP53 mutation (P = 0.049); and inferior LFS was associated with male gender (P = 0.03), haemoglobin < 10 g/dL (P = 0.04) and SRSF2 mutations (P = 0.008). In primary MF, inferior OS was associated with male gender (P = 0.03), haemoglobin < 10 g/dL (P = 0.002), platelet count < 100 × 109/L (P = 0.02), TET2 mutation (P = 0.01) and CUX1 mutation (P = 0.01); and inferior LFS was associated with haemoglobin < 10 g/dL (P = 0.02), platelet count < 100 × 109/L (P = 0.02), TET2 mutations (P = 0.01) and CUX1 mutations (P = 0.04). These results showed that clinical and haematological features and genetic mutations should be considered in MF prognostication.-
dc.languageeng-
dc.publisherSpringer Verlag. The Journal's web site is located at http://link.springer.de/link/service/journals/00277/index.htm-
dc.relation.ispartofAnnals of Hematology-
dc.rightsThe final publication is available at Springer via http://dx.doi.org/10.1007/s00277-018-3563-7-
dc.subjectMyelofibrosis-
dc.subjectPrimary-
dc.subjectSecondary-
dc.subjectNext-generation sequencing-
dc.subjectPrognosis-
dc.titleNext-generation sequencing with a 54-gene panel identified unique mutational profile and prognostic markers in Chinese patients with myelofibrosis-
dc.typeArticle-
dc.identifier.emailSingh, GHH: gillhsh@hku.hk-
dc.identifier.emailIp, HW: iphowan@hku.hk-
dc.identifier.emailYim, RLH: ritayim@hku.hk-
dc.identifier.emailPang, HMH: herbpang@hku.hk-
dc.identifier.emailLee, P: pl85@hku.hk-
dc.identifier.emailSo, JCC: scc@pathology.hku.hk-
dc.identifier.emailLeung, RYY: leungyyr@hku.hk-
dc.identifier.emailPanagiotou, I: gipa@hku.hk-
dc.identifier.emailLam, CCK: ccklam@hku.hk-
dc.identifier.emailKwong, YL: ylkwong@hkucc.hku.hk-
dc.identifier.authoritySingh, GHH=rp01914-
dc.identifier.authorityPang, HMH=rp01857-
dc.identifier.authoritySo, JCC=rp00391-
dc.identifier.authorityPanagiotou, I=rp01725-
dc.identifier.authorityKwong, YL=rp00358-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1007/s00277-018-3563-7-
dc.identifier.pmid30515541-
dc.identifier.scopuseid_2-s2.0-85057971499-
dc.identifier.hkuros296419-
dc.publisher.placeGermany-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats